COM701是一种新型的第一类人源化IgG4单克隆抗体,与含有脊髓灰质炎病毒受体相关免疫球蛋白结构域(PVRIG)高亲和力结合,阻断其与配体PVRL2的相互作用,PVRL2在肿瘤细胞和抗原呈递细胞中表达。阻断PVRIG会导致T/NK细胞的激活增强,并在小鼠模型中抑制肿瘤的生长。此前,COM701已在几种肿瘤类型中显示出单独和联合使用的抗肿...
COM701，作为一种新型的人源化IgG4单克隆抗体，能够与含有脊髓灰质炎病毒受体相关免疫球蛋白结构域（PVRIG）高度结合，阻断其与PVRL2的相互作用，从而增强T/NK细胞的激活，并在小鼠模型中抑制肿瘤生长。此前，COM701已在多种肿瘤类型中显示出单独或联合使用的抗肿瘤和药代动力学活性。在该项1期试验中，...
COM701是一种新型的第一类人源化IgG4单克隆抗体,与含有脊髓灰质炎病毒受体相关免疫球蛋白结构域(PVRIG)高亲和力结合,阻断其与配体PVRL2的相互作用,PVRL2在肿瘤细胞和抗原呈递细胞中表达。阻断PVRIG会导致T/NK细胞的激活增强,并在小鼠模型中抑制肿瘤的生长。此前,COM701已在几种肿瘤类型中显示出单独和联合使用的抗肿...
Both PVRIG and PVRL2 are part of the DNAM axis. In nonclinical experiments using in vitro and animal models we have demonstrated that inhibition of PVRIG leads to enhanced activation of T and NK cells, and that knockout of PVRIG results in tumor growth inhibition in mouse tumor models. We...
抗PVRIG抗体COM701在早期研究中显示出抗肿瘤活性,导语:在I期研究中,实验性抗PVRIG抗体COM701表现出高疾病控制率。Compugen制药公司今日宣布,将在2020年美国癌症研究协会(AACR)年会上提交的数据表明,在I期研究中,实验性抗PVRIG抗体COM701表现出高疾病控制率。
COM701是一种新型、一流的人源化IgG4单克隆抗体,它以高亲和力结合PVRIG,抑制其与其天然配体PVRL2的相互作用,PVRL2在肿瘤细胞和抗原呈递细胞中表达。 此前,COM701已在多种肿瘤类型中单独和组合显示出抗肿瘤和药代动力学活性。 “海得康”发掘国际新药动态,为国内患者提供全球已上市药品的咨询服务,海得康医学顾问咨询...
Background COM701, a novel, first in-class immune checkpoint inhibitor, anti-PVRIG, that leads to activation of T-cells. PVRL2, the ligand of PVRIG, is highly expressed in breast cancer. We have reported preliminary antitumor activity with objective responses [partial responses and a complete ...
In addition, the preliminary correlation between the expression of the PVRIG ligand, PVRL2, and clinical benefit may suggest the potential of baseline PVRL2 as a biomarker to enrich for responding patients. References Abstract #159P; ESMO-IO 2022 Abstract #158P; ESMO-IO; 2022 J Clin Oncol. ...
Background COM701 a novel, 1st in-class, humanized IgG4 monoclonal antibody binds with high affinity to PVRIG, blocking its interaction with its natural ligand PVRL2 expressed in tumor cells and antigen-presenting-cells. We have reported antitumor and pharmacodynamic activity of COM701.1 Anti-PD1/...
Both PVRIG and PVRL2 are part of the DNAM axis as are TIGIT and PD1. Inhibition of PVRIG leads to enhanced activation of T and NK cells, and PVRIG results in tumor growth inhibition in mouse tumor models. We hypothesize that COM701 will demonstrate antitumor activity in pts who are ...